Theralase Technologies (TSXV:TLT) EBITDA Margin % : -205.85% (As of Dec. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Theralase Technologies EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Theralase Technologies's EBITDA for the three months ended in Dec. 2024 was C$-0.84 Mil. Theralase Technologies's Revenue for the three months ended in Dec. 2024 was C$0.41 Mil. Therefore, Theralase Technologies's EBITDA margin for the quarter that ended in Dec. 2024 was -205.85%.

Theralase Technologies EBITDA Margin % Historical Data

The historical data trend for Theralase Technologies's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralase Technologies EBITDA Margin % Chart

Theralase Technologies Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBITDA Margin %

Get a 7-Day Free Trial

-572.34

-528.81

-430.29

-397.57

-383.35

Theralase Technologies Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBITDA Margin %	Get a 7-Day Free Trial															-250.55	-677.27	-1,049.50	-248.70	-205.85

Competitive Comparison of Theralase Technologies's EBITDA Margin %

For the Medical Devices subindustry, Theralase Technologies's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theralase Technologies's EBITDA Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Theralase Technologies's EBITDA Margin % falls into.

Save Embed

;

Save Embed

;

Theralase Technologies EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Theralase Technologies's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-3.96	/	1.033
	=	-383.35 %

Theralase Technologies's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-0.844	/	0.41
	=	-205.85 %

Theralase Technologies (TSXV:TLT) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Theralase Technologies EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Theralase Technologies's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Theralase Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (TSXV:TLT) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

TLTFF:USA TTX:Germany

Address

41 Hollinger Road, Toronto, ON, CAN, M4B 3G4

Website

https://www.theralase.com

Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.

Executives

Matthew Thomas Perraton	Director
Roger John Dumoulin-white	10% Security Holder, Director, Senior Officer
Kristina Maria Hachey	Senior Officer
Arkady Mandel	Senior Officer
Guy John Anderson	Director
Shawn Shirazi	Senior Officer